Table 2.

Eligibility criteria

Category	Inclusion criteria	Exclusion criteria
Demographics	Male or female patients 18 years of age or older	Female patients that are pregnant
Clinical presentation	Patients must have measurable disease according to RECIST criteria and at least one lesion that can be accurately measured in at least one dimension as >10 mm Any patient with documented metastatic or locally advanced, unresectable cancer of the types within the following cohorts: melanoma, non-small cell lung cancer, colorectal cancer ECOG Performance status 0, 1 or 2	Patients who have initiated immunotherapy
Medical history	Patients must be clinically eligible and plan to initiate therapy with an anti-neoplastic agent that works by immune checkpoint blockade, anti-PD-1, anti-CTLA-4 or anti-PD-L1: Pembrolizumab (Keytruda) Nivolumab (Opdivo) Ipilimumab (Yervoy) Durvalumab (Imfinzi) Cemiplimab (Libtayo) Atezolizumab (Tecentriq) Avelumab (Bavencio) Patients must be able to follow the study visit schedule and be willing to provide up to 20 mL of peripheral blood samples at the indicated time points	Patients with a history of bone marrow or organ transplant, a medical condition that would place the patient at risk as a result of blood donation, such as bleeding disorder, or a serious medical condition that may adversely affect the ability to participate in the study
Provider-based criteria	Selected by their HCP to receive ctDNA assay according to the current evidence-informed schedule as part of their routine of practice

ctDNA, circulating tumour DNA; CTLA-4, cytotoxic T‐lymphocyte associated antigen-4; HCP, healthcare provider; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand 1.